GERN

Geron Corporation is a late-stage clinical biopharmaceutical company developing novel therapies for hematologic malignancies. The company's lead product candidate, imetelstat, is a telomerase inhibitor in clinical development for myelofibrosis and myelodysplastic syndromes (MDS). Geron's therapeutic approach targets cancer stem cells by inhibiting telomerase, an enzyme that allows cancer cells to divide indefinitely. The company received FDA approval for Rytelo (imetelstat) for lower-risk MDS in June 2024, marking its transition to a commercial-stage biotechnology company.